N. Serum uric acid is associated with cardiac diastolic dysfunction among women with preserved ejection fraction. Am J Physiol Heart Circ Physiol 309: H986 -H994, 2015. First published July 25, 2015 doi:10.1152/ajpheart.00402.2015.-Serum uric acid (SUA) is associated with the severity and prognosis of systolic heart failure. We investigated the potential association between SUA and cardiac diastolic dysfunction among total of 744 cardiac patients (202 women and 542 men) who had preserved left ventricular ejection fraction. Presence of diastolic dysfunction was assessed by echocardiographic data, plasma B-type natriuretic peptide concentration, and left ventricular hypertrophy. Univariate analysis showed that the prevalence of diastolic dysfunction increased with increasing SUA value in women, but not in men. When sex-nonspecific SUA quartiles were used, multivariate logistic regression analysis, among female patients who were not taking uric acid lowering medication, showed that the third (SUA, 5.7-6.4 mg) and the fourth (SUA, Ն6.5 mg/dl) SUA quartiles were associated with diastolic dysfunction with an odds ratio of 3.25 (P Ͻ 0.05) and 8.06 (P Ͻ 0.001), respectively, when compared with the first SUA quartile (Յ4.7 mg/dl). When sex-specific SUA quartiles were used among these population, multivariate logistic regression analysis showed that the fourth SUA quartile (Ն5.7 mg/dl) was associated with diastolic dysfunction with an odds ratio of 5.34 (P Ͻ 0.05) when compared with the first SUA quartile (Յ4.1 mg/dl). By contrast, the relationship between SUA and diastolic dysfunction was not significant in men, irrespective of which of the sex-nonspecific or sex-specific SUA quartiles were used. These data indicated that among cardiac patients with preserved ejection fraction, SUA was significantly associated with diastolic dysfunction in women but not in men. ALONGSIDE THE AGING POPULATION, the prevalence of heart failure with preserved ejection fraction, or diastolic heart failure, is increasing, and this increase is more prominent in women than in men, who demonstrate striking disparity with regard to heart failure with reduced ejection fraction (2, 3, 25) . This disparity might be explained by the fact that aging-associated concentric ventricular remodeling is greater in the female heart (35). In addition to sex difference, several clinical characteristics are known to be associated with heart failure with preserved ejection fraction including older age, hypertension, obesity, diabetes, and potassium concentration (23). The prognosis for diastolic heart failure may be as poor as that for systolic heart failure (11, 31), and most therapies that have been shown to be effective for systolic heart failure seem to be least effective for diastolic heart failure (11, 15, 26, 32, 42) . Thus factors that are not only related to diastolic dysfunction risk but also potentially modifiable by lifestyle interventions or certain medication need to be identified for the better management of diastolic cardiac dysfunction, especially in women.
ALONGSIDE THE AGING POPULATION, the prevalence of heart failure with preserved ejection fraction, or diastolic heart failure, is increasing, and this increase is more prominent in women than in men, who demonstrate striking disparity with regard to heart failure with reduced ejection fraction (2, 3, 25) . This disparity might be explained by the fact that aging-associated concentric ventricular remodeling is greater in the female heart (35) . In addition to sex difference, several clinical characteristics are known to be associated with heart failure with preserved ejection fraction including older age, hypertension, obesity, diabetes, and potassium concentration (23) . The prognosis for diastolic heart failure may be as poor as that for systolic heart failure (11, 31) , and most therapies that have been shown to be effective for systolic heart failure seem to be least effective for diastolic heart failure (11, 15, 26, 32, 42) . Thus factors that are not only related to diastolic dysfunction risk but also potentially modifiable by lifestyle interventions or certain medication need to be identified for the better management of diastolic cardiac dysfunction, especially in women.
It has been reported that elevated serum uric acid (SUA) levels are associated with left ventricular (LV) hypertrophy and impaired LV diastolic relaxation, although the underlying mechanism is poorly understood. In addition, several recent studies demonstrated, albeit by analyzing relatively small sample sizes, that elevated SUA may be associated with increased risk of LV diastolic dysfunction among a selected population (13, 38) . Of note, the finding that a xanthine oxidase inhibitor that decreased SUA level also improved cardiac diastolic relaxation in mice fed a Western diet suggested that SUA might be a modifiable factor associated with diastolic dysfunction.
On the other hand, there are substantial differences in SUA levels between women and men of various ethnicities (7, 12, 37) , and it is unclear whether there is a sex difference in the SUA threshold at which the risk of diastolic dysfunction increases. To this end, we investigated whether there is an association between SUA and cardiac diastolic dysfunction and, if so, whether it differs according to sex among cardiac patients with preserved LV ejection fraction (LVEF).
METHODS
Study population. The current retrospective study was approved by the Ethics Committee of Osaka Medical College. In total, 2,076 patients who were admitted to the Cardiology Department between November 2011 and June 2014 and from whom SUA data were available provided written, informed consent. From these subjects, the patients who met the following conditions were excluded: 1) insufficient echocardiographic data to estimate LVEF, 2) LVEF of Ͻ50%, 3) other than sinus rhythm, 4) insufficient data regarding assessment of diastolic dysfunction, and 5) undergoing maintenance hemodialysis. After these exclusions, 744 patients were enrolled in the current study ( Fig. 1 ). Among these, 75 patients were taking uric acid (UA)-lowering drug(s).
Laboratory analysis. C-reactive protein and B-type natriuretic peptide (BNP) were measured by routine laboratory methods. The estimated glomerular filtration rate (eGFR) was calculated by the following modification of diet in renal disease equation for Japanese subjects: eGFR ϭ 194 ϫ (serum creatinine) Ϫ1.094 ϫ (age) Ϫ0.287 (ϫ 0.739, when female) (27) . Log transformed eGFR was designated log(eGFR).
Echocardiography, mitral blood flow velocity, and tissue-Doppler imaging. Echocardiographic examinations were performed as previously described (36) . Briefly, for calculation of the LV end-diastolic dimension (LVDd), interventricular septal thickness (IVST) and posterior wall thickness (PWT) were measured at end diastole. For LV mass (LVM), we used the formula proposed by Devereux et al. (8) with modification: 0.8 (40) . LVM index (LVMI) was calculated as the ratio of LVM to the body surface area. LV hypertrophy was defined to be present when the LVMI was Ͼ118 g/m 2 (men) or Ͼ108 g/m 2 (women) (34) . LVEF was calculated based on the Teichholz method. Transmitral inflow was recorded by blood flow Doppler recordings at the mitral valve leaflet tips in the apical four-chamber view. The deceleration time of the E wave (DcT) and peak velocities of early filling (E) and atrial filling (A) were measured. The average of the early peak diastolic mitral annulus velocity obtained at the septal and lateral annulus was measured using pulsed wave tissue Doppler imaging, which was designated e=. Diastolic dysfunction was diagnosed when any the following criteria were met: 1) E/e= Ն 15, 2) 15 Ͼ E/e= Ն 8 and BNP Ն 200 pg/ml, 3) 15 Ͼ E/e= Ն 8, E/A Ͻ 0.5, and DcT Ն 280 ms, or 4) 15 Ͼ E/e= Ն 8, E/A Ͻ 0.5 and presence of LV hypertrophy. Statistical analysis. Baseline characteristics were assessed with standard descriptive statistics. Data were expressed as either means Ϯ SD or median and interquartile range (IQR). A Spearman rank correlation test was used to assess the correlation between two variables. For multivariate analysis, multivariate linear regression and multivariate logistic regression analyses were used. Data analysis was performed by SPSS statistics version 22.0 (IBM, Armonk, NY). A value of P Ͻ 0.05 was taken to be statistically significant.
RESULTS

Patient characteristics.
Among 744 subjects enrolled, 202 were women and 542 were men. Male patients were slightly, but significantly, younger than female patients ( Table 1) . The prevalence of moderate to severe heart failure symptoms (New York Heart Association functional class III/IV) did not differ significantly between women and men. Prevalence of diastolic dysfunction in women was more than twice as much as that in men. In addition, when compared with those without diastolic dysfunction, patients with diastolic dysfunction were significantly older (74.0 Ϯ 8.9 vs. 67.5 Ϯ 11.2 yr, P Ͻ 0.001).
Although systolic blood pressure on admission did not signif- The median SUA level was significantly higher in men (Table 2) , and this remained so when subjects taking UAlowering drugs were excluded from the analysis (data not shown). When the proportion of women and men according to SUA octile was determined, it was apparent that the proportion of men increased with increasing SUA, whereas the prevalence of women and men was found to be almost the same in the lowest SUA octile in the study population (Fig. 2) .
Fifty-nine (10.9%) of 542 male patients and 33 (16.3%) of 202 female patients were taking either loop or thiazide diuretic medication. SUA was significantly higher in patients who were taking either loop/thiazide diuretics (median, 5.9 mg/dl; and IQR, 5.0 -6.6 mg/dl) compared with those taking neither diuretic drug (median, 5.6 mg/dl; and IQR, 4.6 -6.3 mg/dl; P Ͻ 0.001). Patients with New York Heart Association III/IV symptoms had median SUA level of 6.2 mg/dl (IQR, 5.1-7.6 mg/dl), which was significantly higher than that in patients who had, if any, milder heart failure symptoms (median, 5.6 mg/dl; and IQR, 4.7-6.4 mg/dl; P ϭ 0.015). Values of age, body mass index, systolic blood pressure, and pulse rate are means Ϯ SD; n, number of patients. NYHA, New York Heart Association; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; UA, uric acid. Correlation between serum UA and factors related with diastolic dysfunction. SUA was significantly correlated with eGFR both in women (R ϭ Ϫ0.517; P Ͻ 0.001) and in men (R ϭ Ϫ0.398; P Ͻ 0.001). Among factors used for the assessment of diastolic dysfunction, E-to-A ratio, E-to-e= ratio, and BNP level were significantly correlated in women, but not in men (Table 3) . On the other hand, LVMI showed a significantly correlation with SUA in both sexes.
Relationship between sex-nonspecific SUA octile and diastolic dysfunction. There was a positive association between sex-nonspecific SUA octile and prevalence of diastolic dysfunction in women (P Ͻ 0.001, by 2 -test); however, this association was not significant in men (P ϭ 0.515) (Fig. 3A) . Essentially, the same results were obtained both in women (P Ͻ 0.001) and men (P ϭ 0.555) after excluding patients with UA-lowering medication (Fig. 3B) .
Logistic regression analysis of the relationship with diastolic dysfunction using sex-nonspecific SUA quartiles. The relationship between SUA quartiles and diastolic dysfunction was next investigated separately for each sex by logistic regression analysis (Table 4) . In this analysis, sex-nonspecific SUA quartiles were used. In women, when compared with the first SUA quartile, logistic regression analysis showed that the third and fourth SUA quartile was associated with diastolic dysfunction with an odds ratio of 3.49 and 9.46, respectively, after adjusting for age (model 1). After addition of log(eGFR), systolic blood pressure, and pulse rate as independent variables (model 2), association between both the third and fourth SUA quartiles and diastolic dysfunction in women retained statistical significance. After further adjustment of the statistical model by use of loop or thiazide diuretic (model 3), the highest SUA quartile retained statistically significant association with diastolic dysfunction in women. When limited to the female patients without UA-lowering medication, essentially the same results were obtained, but the association between the third, as well as fourth, SUA quartile with diastolic dysfunction was found to be statistically significant.
In men, on the other hand, higher SUA quartiles were not associated with diastolic dysfunction in any of the models tested. In addition, when the analysis was performed for patients who were not taking UA-lowering drugs, essentially the same results were obtained.
Relationship between sex-specific SUA octile and diastolic dysfunction. We then analyzed the relationship between sexspecific SUA octile and diastolic dysfunction. As shown in Fig.  4 , there was a positive association between sex-specific SUA octile and prevalence of diastolic dysfunction in women, but this association was not significant in men (Fig. 4A) . Essentially, the same results were obtained in both sexes after excluding patients with UA-lowering medication (Fig. 4B) . Patient characteristics according to SUA quartile in women and those in men are described in Tables 5 and 6 , respectively. Loop diuretic was more frequently used in patients, either men or women, with higher SUA levels.
Logistic regression analysis of the relationship with diastolic dysfunction using sex-specific SUA quartiles. We next analyzed the relationship between sex-specific SUA quartiles and diastolic dysfunction. LVMI (in g/m 2 ) in the first through fourth sex-specific SUA quartile among female patients was 85.2 (67.3-102.2), 89.7 (81.5-102.3), 100.9 (83.7-114.1), and 2), respectively (P ϭ 0.008). In the logistic regression analysis using diastolic dysfunction as the dependent variable, the first through fourth SUA quartiles in women were designated fQ1, fQ2, fQ3, and fQ4, and those in men were designated mQ1, mQ2, mQ3, and mQ4 (Table 7 ). In this model, fQ4 was significantly associated with diastolic dysfunction with an odds ratio of 4.64 after the adjustment of age, log(eGFR), systolic blood pressure, pulse rate, and use of loop/thiazide diuretic (model 3). When the analysis was performed for female patients who were not taking UA-lowering drugs, the odds ratio of fQ4 for the diastolic dysfunction was calculated to be 5.34, when using fQ1 as a reference. In addition, when antidiabetic medication was added as an independent variable in model 3, the odds ratio of fQ4 for the diastolic dysfunction slightly decreased to 5.15 [95% confidence interval (CI), 1.41-18.8; P ϭ 0.013] but retained statistical significance. When only female subjects who were not taking either UA-lowering or loop/thiazide diuretic medication were analyzed, the odds ratio of fQ4 for the diastolic dysfunction was increased to 6.79 (95% CI, 1.61-28.6; P ϭ 0.009) compared with the fQ1 in model 2, that is, after the adjustment of age, log(eGFR), systolic blood pressure, and pulse rate. When body mass index (BMI) was added an additional covariate in model 3, the odds ratio of fQ4 for diastolic dysfunction became 6.30 (95% CI, 1.68 -23.6; P ϭ 0.006) and 6.81 (95% CI, 1.81-25.6; P ϭ 0.005), respectively, among the overall female patients and females patients without UA-lowering medication, among the latter of which subgroup, BMI was not found to be significantly associated with diastolic dysfunction (odds ratio, 0.70; and 95% CI, 0.48 -1.03; P ϭ 0.073). When peripheral artery disease was added as an additional covariate in model 3, the odds ratio of fQ4 for diastolic dysfunction Fig. 3 . Prevalence of diastolic dysfunction according to sex-nonspecific uric acid (UA) octile for each sex. A: whole study population. B: study sample after excluding those who were taking UA-lowering medication. There was a positive association between SUA octile and prevalence of diastolic dysfunction in women (P Ͻ 0.001, by 2 -test), but not in men among whole study population (A), as well as among those who were not taking UA-lowering medication (B). overall female patients and females patients without UAlowering medication, among the latter of which subgroup, peripheral artery disease was not found to be significantly associated with diastolic dysfunction (odds ratio, 1.32; and 95% CI, 0.36 -4.79; P ϭ 0677).
On the other hand, in men, either of mQ2, mQ3, or mQ4 was associated with diastolic dysfunction in any model used. When the analysis was performed for male patients who were not taking UA-lowering drugs, essentially the same results were obtained. Even after BMI was added an additional covariate in model 3, association between SUA quartile and diastolic dysfunction was not statistically significant among either of overall male patients or male patient without UA-lowering medication (data not shown).
DISCUSSION
In the current study, we analyzed the relationship between SUA and cardiac diastolic dysfunction among individuals who had preserved LVEF. It was found that SUA was associated with diastolic dysfunction in women, but not in men. Among female patients who were not taking UA-lowering medication, Fig. 4 . Prevalence of diastolic dysfunction according to sex-specific UA octile for each sex. A: whole study population. B: study sample after excluding those who were taking UA-lowering medication. There was a positive association between SUA octile and prevalence of diastolic dysfunction in women, but not in men among whole study population (A), as well as among those who were not taking UA-lowering medication (B). P values are by 2 -test. the third (SUA, 5.7-6.4 mg) and fourth sex-nonspecific SUA quartiles (Ն6.5 mg/dl) were significantly associated with diastolic dysfunction with an odds ratio of 3.29 and 8.30, respectively, compared with the first SUA quartile (Յ4.7 mg/dl) in the model with adjustment for multiple variables, including age, renal function, blood pressure, pulse rate, and diuretic use, indicating that female patients who had a relatively higher SUA levels, even within the normal range, are at risk of diastolic dysfunction. Among this population, the fourth sexspecific SUA quartile (Ն5.7 mg/dl) was significantly associated with diastolic dysfunction with an odds ratio of 5.34 compared with the first SUA quartile (Յ4.1 mg/dl) by multivariate logistic regression analysis. The prognostic importance of SUA in patients with systolic heart failure has been reported in several previous studies; elevation of SUA, which is not a rare situation (10), was reported to predict morbidity and mortality in systolic heart failure (19, 41) , and SUA may provide greater information than BNP in terms of prognosis among patients with dilated cardiomyopathy (21) . The mechanism underlying these associations remains uncertain; however, elevation of SUA may reflect increased xanthine oxidase activity leading to enhanced oxidative stress, which may play a role in the development of cardiac remodeling and dysfunction (16) . Several studies have previously examined whether SUA-lowering therapy leads to clinical and functional improvement of heart failure; however, the results are not consistent (6, 14, 20, 30) .
As compared with systolic heart failure, the relationship between cardiac diastolic dysfunction and SUA has been analyzed to a lesser extent. Ciccoira et al. (5) showed that among heart failure patients with dilated cardiomyopathy, SUA showed a significant correlation with several diastolic parameters including E velocity, E-to-A ratio, and DcT. In addition, Tang et al. (38) analyzed data from patients who had preserved LVEF and reported that SUA was associated with diastolic heart failure; however, they did not use tissue-Doppler assessment in the estimation of diastolic dysfunction, nor did they adjust their statistical model for renal function. To the best of our knowledge, the current report is the first to demonstrate a sex-specific association between SUA and diastolic dysfunction.
In the current study, a positive association between SUA and prevalence of diastolic dysfunction was observed only in women. Considering that females with an SUA value of Ն5.7 mg/dl (i.e., in the third or the fourth sex-nonspecific SUA quartile) had a significantly higher prevalence of diastolic dysfunction compared with those with SUA Յ4.7 mg/dl in a multivariate model and that more than a quarter of female patients fell into the former category, the importance of this observation should not be underestimated (Fig. 2) .
It was reported in the study from Japan that among hospitalized patients with congestive heart failure, the number of patients with preserved systolic function (n ϭ 73) was almost comparable with those with depressed systolic function (n ϭ 73) (39) . Even taking into consideration that the number of patients with moderate to severe heart failure was small, prevalence of diastolic dysfunction seemed relatively small in the current study. This may be due in part to the difference in the method used to identify the diastolic dysfunction and to the characteristics of the department of the institute. These possibilities need further investigation. The potential mechanism underlying the sex-specific association between higher SUA and diastolic dysfunction remains unclear; however, there are some possibilities. It has been reported that patients with elevated SUA are more likely to have increased insulin resistance or metabolic syndrome (18) . In addition, subjects with metabolic syndrome are more likely to have diastolic dysfunction (9, 17) , and this association may be stronger or present exclusively in women (22, 24) . More recently, Nagayama et al. (29) reported that cardio-ankle vascular index, a marker of arterial stiffness, was associated with SUA level in both sexes; however, an increase in cardio-ankle vascular index was observed for a lower SUA range in women compared with men (29) . Several studies demonstrated that arterial stiffness is associated with LV diastolic function (4, 28) . Therefore, it is possible that differences in the strength of the link between SUA and insulin resistance or arterial stiffness may explain the sex-specific relationship between SUA and diastolic dysfunction. In addition, most, if not all, of the female patients were considered to be postmenopausal, and female patients with higher SUA quartile were older than those in lower SUA quartile, although not significant. Considering that serum estradiol level may show further gradual decrease in the post-menopause years (33) and that estradiol may affect cardiac diastolic function (1), it is possible that serum estrogen may have a link with the observed association between SUA and diastolic dysfunction in women. These possibilities need further investigation.
More than 10% of the current study patients were taking either loop or thiazide diuretic, and patients who were taking loop/thiazide diuretic had significantly higher SUA than those without such medication. It is possible that patients with heart failure may more likely be taking diuretic medication and thus relatively high SUA level, which may lead to the apparent association between high SUA and cardiac dysfunction. However, in the current study, it was confirmed that the relationship between SUA and diastolic dysfunction retained statistical significance after the adjustment of diuretic use. In addition, in female patient who were not taking loop/thiazide diuretic or UA-lowering medication, the odds ratio of the fourth (sexspecific) SUA quartile for the diastolic dysfunction was 6.79 (95% CI, 1.61-28.6; P ϭ 0.009). These findings support that notion that association between SUA and diastolic dysfunction in women was not explained by the diuretic use. Nevertheless, if circulating UA plays a role in the development of diastolic dysfunction, association between SUA and diastolic dysfunction can be observed among those who were taking diuretic medication. In the current study, however, the number of patients who were taking diuretic medication was not large; therefore, this point should be elucidated in future studies.
There are several limitations in the current study. First, the study population comprised cardiac inpatients, and the results may not be applicable to the general population. Second, we used the blood and echocardiographic data at the time of admission in principle; therefore, data may not have been obtained in the fasting condition, which may affect the several blood data, including SUA and serum creatinine. Third, as the number of patients with diastolic dysfunction in either sex was relatively small, the findings, especially regarding to sex difference, should carefully be interpreted. It should be noted that owing to the small number of patients with diastolic dysfunction, the statistical model was not adjusted for several variables that differ between the sexes significantly; these include the background disorders and medications used, some of which might potentially be related with cardiac function, such as angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Fourth, owing to the cross-sectional nature of the study, we cannot conclude that uric-lowering interventions would be effective in the amelioration of diastolic dysfunction. The Japanese guideline described that drug therapy for asymptomatic hyperuricemia is implemented when serum urate levels are 8.0 mg/dl or higher as a general indicator but should be undertaken with caution. On the other hand, the guideline also pointed out that among women, the risk of lifestyle diseases increases with rises in serum urate levels, even if serum urate levels are below 7.0 mg/dl. This is mainly because of the lack of randomized intervention trial for the SUA-lowering therapy. To answer this question, clinical trial investigating whether UA-lowering medication improves the parameters related to the diastolic function is now in progress (Unique trial number, UMIN000011961; URL, https://upload.umin.ac.jp/cgi-openbin/ctr/ctr.cgi?functionϭbrows&actionϭbrows&recptnoϭ R000013974&typeϭsummary&languageϭE). It was found in the current study that female patients with higher SUA levels were more likely to have diastolic dysfunction; however, before concluding whether UA-lowering therapy are indicated for female subjects with high SUA for the purpose of preserving cardiac diastolic function and whether routine SUA measurement is indicated for these patients in outpatient setting, one should wait for the results of such clinical trials.
In conclusion, among cardiac patients with preserved ejection fraction, SUA was significantly positively associated with diastolic dysfunction only in women, and this association was independent of age, renal function, systolic blood pressure, pulse rate, and diuretic use. Whether UA-lowering therapy would effectively ameliorate cardiac diastolic function, and so whether there is sex specificity, should be analyzed in future studies.
